drugset / Trial / NCT03485456
DPI-Tobra-Kind Cyclops® in Children With Cystic Fibrosis
NaSingle-groupOpen-labelTreatment
Summary
The goal is to investigate the pharmacokinetic properties of dry powder tobramycin via the Cyclops® at different dosages in children with cystic fibrosis, together with the local tolerability.
Timeline
- Start
- 2019-05-29
- Primary completion
- 2020-11-13
- Completion
- 2022-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tobramycin | Unknown | 30 mg | Inhaled |
| Subject | Tobramycin | Unknown | 60 mg | Inhaled |
| Subject | Tobramycin | Unknown | 90 mg | Inhaled |
| Subject | Tobramycin | Unknown | 300 mg | Inhaled |